Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction (NCT05892042) | Clinical Trial Compass
UnknownNot Applicable
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
China320 participantsStarted 2023-05-01
Plain-language summary
Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Established ST segment elevation myocardial infarction within 7 days Left ventricular thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE.
Ongoing treatment with dual anti-platelet therapy according to ESC/AHA guidelines at the time of randomization
Exclusion Criteria:
Clinically or hemodynamically unstable planed major surgeon such as CABG or Valve replacement within next 12 months Concomitant condition that requires anti- coagulation therapy, such as AF, DVT.
Any contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who is currently pregnant, or breastfeeding serious impaired renal and liver functions life expectancy less than 1 year can not provide consent
What they're measuring
1
Percentage of participants with the first occurrence of Stroke and other systemic embolism